https://www.selleckchem.com/
The 'obesity paradox' suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those receiving targeted and immune checkpoint inhibitor therapy. Higher BMI is also associated with higher incidences of treatment-related adverse events (TRAEs). This study assesses whether BMI is associated with survival outcomes and adverse events in metastatic melanoma patients with systemic therapy. This multicentric retrospective study, conducted from 1 March 2013 to 29 April 2019, enrolled adults with
Me gusta
Comentario
Compartir
